Showing 1861-1870 of 9909 results for "".
Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toThe Microbiome in Acne: Where are We Now?
https://practicaldermatology.com/topics/acne-rosacea/the-microbiome-in-acne-where-are-we-now/23731/As research reveals connections of the microbiome to skin disease, clinicians may discover new approaches to managing the disease.Part 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Which Probiotic for Which Disease? Part 1
https://practicaldermatology.com/topics/atopic-dermatitis/which-probiotic-for-which-disease-part-1/23550/Enhanced interest in probiotics means clinicians need to pick the best strain for common dermatologic conditions.Verrucous Carcinoma of the Foot
https://practicaldermatology.com/youngmd-connect/resident-resource-center/verrucous-carcinoma-of-the-foot/23241/Healing by Secondary IntentionTreating Psoriasis with FDA-Approved Medications in 2020
https://practicaldermatology.com/topics/psoriasis/treating-psoriasis-with-fda-approved-medications-in-2020/23212/A reference for all of the FDA-approved medications separated into topical treatments and systemic treatments.Part 7, 1726 nm lasers: When a patient doesn’t improve: Doctors discuss “pearls” of wisdom
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24345/Chapter 7 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about when a patient doesn’t improve: Doctors discuss “pearls” of wisdom.Pearls for Management of Pediatric Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/pearls-pediatric-management-atopic-dermatitis/27122/At the recently held 2024 American Academy of Dermatology (AAD) Innovation Academy dermatologist Lisa Swanson, MD, FAAD, presented new insights into pediatric atopic dermatitis (AD), emphasizing its wide-ranging impact on children's health, including increased risks of food allergies, infections, anAAD Wrap: What To Know from Dermatology’s Biggest Meeting
https://practicaldermatology.com/issues/april-2025/aad-wrap-what-to-know-from-dermatologys-biggest-meeting/35623/The 2025 American Academy of Dermatology (AAD) Annual Meeting brought together the dermatology community this past March to exchange groundbreaking research, innovative treatments, and technological advancements. For 4 days in Orlando, the meeting served as the hub of the dermatology profession, delThe Impact of Clascoterone Topical Cream, 1%: The US Experience 4 Years After Approval and Clinical Expectations for Acne Patients in Other Regions of the World
https://practicaldermatology.com/topics/acne-rosacea/Impact-Clascoterone-Topical-Cream/32830/Clascoterone topical cream, 1% (Winlevi), approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older. The safety and efficacy were supported by two succe